Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
Sight Sciences announced the appointment of Alison “Ali” Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023.
“I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive toward profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will provide an immediate and valuable impact,” Paul Badawi, co-founder and Chief Executive Officer of Sight Sciences, said in a company news release. “A proven entrepreneur and executive, Ali will partner with our team to advance our strategic plan and ensure we have the appropriate financial infrastructure to support our growth. I would like to thank Jim Rodberg for his ever-increasing leadership and commitment to our mission as he stepped into the interim Chief Financial Officer and Treasurer role and managed the finance organization exceptionally well.”
Ms. Bauerlein joins Sight Sciences from Inogen, a medical technology company offering innovative respiratory products for use in the homecare setting. She cofounded Inogen in 2001 and served as its Chief Financial Officer from 2009 through 2021. Ms. Bauerlein served as a member of the board of directors of Pear Therapeutics, a software-based digital therapeutics company, since December 2021, and as a member of the board of directors of Gelesis Holdings, a biotherapeutics company, since January 2022.
“Sight Sciences is a leader in eye care technology innovation with a portfolio and pipeline of products disrupting two distinct multibillion dollar markets and generating top-tier revenue growth. I have firsthand experience with this stage of transformational growth and development and am excited to leverage my background in high growth medtech to help Sight Sciences achieve its fullest potential," Ms. Bauerlein said. "I look forward to working with Paul and the Sight Sciences team to support our current growth and profitability plans, while improving the lives of our patients and striving to create maximum value for the ophthalmic community and our stockholders.”